Patients with sporadic and familial amyotrophic lateral sclerosis found value in genetic testing

20Citations
Citations of this article
34Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Background: Amyotrophic lateral sclerosis (ALS) is increasingly recognized as a genetic disease. There is no consensus, however, as to the role of genetic testing in the care of the ALS patient. Methods: We conducted a survey to study patient access, attitudes, and experience with ALS genetic testing among patients enrolled in a US ALS registry. Results: Among 449 survey respondents, 156 (34.7%) were offered testing and 105 of 156 (67.3%) completed testing. The majority of respondents with familial ALS (fALS) (31/45, 68.9%) were offered testing, while a minority of respondents with sporadic ALS (sALS) (111/404, 27.5%) were offered testing (p =.00001). Comparison of mean test experience scores between groups revealed that respondents with fALS were no more likely to report a favorable experience with genetic testing than those with sALS (p =.51). Respondents who saw a genetic counselor did not have significantly different test experience scores, compared to those who did not (p =.14). In addition, no differences in test experience scores were observed between those who received positive or negative genetic test results (p =.98). Conclusion: These data indicate that patients with ALS found value in clinical genetic testing.

Cite

CITATION STYLE

APA

Wagner, K. N., Nagaraja, H. N., Allain, D. C., Quick, A., Kolb, S. J., & Roggenbuck, J. (2018). Patients with sporadic and familial amyotrophic lateral sclerosis found value in genetic testing. Molecular Genetics and Genomic Medicine, 6(2), 224–229. https://doi.org/10.1002/mgg3.360

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free